Overview of Olfen-75 Sr

Property	Description
Active ingredient	Diclofenac Sodium
Form	Prolonged-Release Tablet (SR)
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Systemic relief of pain and inflammation
Origin	Synthetic (Phenylacetic acid derivative)

Defining Olfen-75 Sr: Classification and Active Ingredient

Olfen-75 Sr is a specific pharmaceutical preparation whose core active substance is Diclofenac Sodium, which is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This single-ingredient medication is a synthetic compound, a monosodium salt derived from the chemical family of phenylacetic acid derivatives. The fundamental classification as an NSAID places it in a group of agents that operate by inhibiting key enzymes, which ultimately curtails the production of prostaglandins—the biological mediators of pain and swelling. Diclofenac Sodium is widely clinically recognized for its efficacy in managing inflammatory processes.

The Significance of the Prolonged-Release (SR) Form

The physical presentation of Olfen-75 Sr is a specialized prolonged-release tablet, intended for oral ingestion. This formulation is distinguished by the designation SR (Sustained Release), a key feature that separates it from standard, immediate-release Diclofenac forms. The SR design utilizes a matrix of pharmaceutical excipients to ensure the Diclofenac Sodium is released slowly and consistently over an extended duration, optimizing the maintenance of therapeutic drug levels. This prolonged effect is a differentiating feature specifically designed for sustained action.

General Purpose: What Does Olfen-75 Sr Help Relieve?

The general therapeutic purpose of Olfen-75 Sr is to provide systemic relief from signs associated with inflammation and pain. Due to its NSAID classification, its function delivers a three-part effect: it acts as an analgesic to reduce pain perception, an anti-inflammatory agent to mitigate associated swelling and redness, and an antipyretic to help reduce an elevated body temperature. The continuous action provided by the SR formulation supports sustained mitigation of discomfort and the physiological effects of inflammation, such as the discomfort often experienced in conditions affecting joints and muscles.

Regulatory References

NIH StatPearls

What side effects are possible with Olfen-75 Sr?

The official safety profile for Olfen-75 Sr (diclofenac) is defined by a range of adverse reactions, from common events to serious, potentially fatal risks. Regulatory bodies strictly organize these risks by frequency and system.

Serious and Dose/Duration-Related Risks

The medicine is associated with an increased risk of serious cardiovascular thrombotic events (such as myocardial infarction and stroke), which can be fatal. This risk may increase with higher doses and longer duration of use. Serious gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines, have also been reported and can occur without warning symptoms.

Adverse Reactions by Frequency

Adverse reactions are classified according to frequency found in official regulatory documents:

Common: Includes gastrointestinal disturbances (nausea, vomiting, diarrhea, indigestion), abdominal pain, headache, dizziness, and elevated liver enzyme levels.
Rare: Includes hypersensitivity and anaphylactic/anaphylactoid reactions, as well as gastrointestinal ulceration and bleeding.
Very Rare: Includes potentially fatal severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) and severe liver reactions (e.g., fulminant hepatitis, hepatic failure).

Regulatory Safety Restrictions

Use is subject to specific contraindications including the third trimester of pregnancy due to risk to the fetus, established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, and severe heart, hepatic, or renal failure. Close medical surveillance is advised for elderly patients and those with a history of gastrointestinal disorders. The lowest effective dose should be used for the shortest possible duration to minimize risks.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The following information is derived from authoritative government drug safety documents regarding acute intoxication with diclofenac, the active ingredient in Olfen-75 Sr.

Documented Overdose Presentations

Symptoms following an acute overdose are primarily linked to the gastrointestinal (GI) and central nervous systems (CNS). Common signs include nausea, vomiting, stomach pain, and GI bleeding (seen as blood in vomit or black, tarry stools). Central nervous system effects may present as drowsiness, dizziness, unsteadiness, confusion, agitation, or severe headache.

Life-threatening outcomes in severe cases include convulsions (seizures), coma, acute kidney failure (marked by little or no urine output), and large internal bleeding.

Required Emergency Actions

Immediate medical help is required if an overdose is suspected. Call your local emergency number or the poison control center immediately. Provide the following information: the person's age, weight, condition, the product name (ingredients and strength), the time, and the amount swallowed.

There is no specific antidote for diclofenac overdose. Management is supportive and symptomatic, and may include measures to prevent drug absorption, such as activated charcoal, and monitoring of vital signs, blood work, and ECG.

Population Considerations

A large overdose can be very harmful to children and adults. Individuals with pre-existing conditions like asthma may experience exacerbated wheezing or trouble breathing in an overdose setting. Older patients are at greater risk for serious gastrointestinal events.

Therapeutic Uses of Olfen-75 Sr

What Olfen-75 Sr treats: main uses and benefits

Diclofenac, the active component in this medication, is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states across a range of conditions. It may be part of symptomatic management for conditions characterized by periods of heightened symptoms, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for acute episodes like migraine headaches or painful menstrual periods.

Clinical Scope and Patient Benefit

This medicine is applied in clinical settings that involve acute or unstable symptom patterns, providing support that helps ease the overall burden of symptoms. It assists with supporting functional stability during periods of increased distress or discomfort, which is particularly relevant when symptoms become temporarily overwhelming.

“It offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports the patient during phases of heightened discomfort.”

Quick Fact: Relief for Acute Discomfort and Strain

Management of Fluctuating Symptom Patterns

Olfen-75 Sr is considered relevant for conditions involving episodic or fluctuating manifestations where short-term symptomatic assistance is needed. It helps address symptom clusters that create noticeable physiological strain or interfere with daily functioning, contributing to easing the overall symptom load during symptomatic periods.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile

Olfen-75 Sr is formally approved for use in adults (18 years and older). Its use is not recommended in children and adolescents under 18 years of age, as safety and efficacy have not been established in the pediatric population. Elderly patients (65 and older) may use the medicine but require caution, particularly if frail or having a low body weight.

Absolute Contraindications

The medicine must not be used by populations with specific pre-existing conditions, as stated by regulatory bodies:

Allergy History: Known hypersensitivity to diclofenac, or a history of allergic reactions (e.g., asthma, hives) after taking aspirin or other NSAIDs.
Gastrointestinal: Active gastric or intestinal ulceration, bleeding, or perforation, including established Inflammatory Bowel Disease.
Cardiovascular: Established congestive heart failure (NYHA class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. It is also contraindicated for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Organ Failure: Severe hepatic failure (Child-Pugh Class C) or severe renal failure.
Pregnancy: Women in the third trimester of pregnancy (after 30 weeks gestation).

Use Restrictions

Caution is advised for patients with mild to moderate renal or hepatic impairment. Treatment is generally not recommended in patients with established cardiovascular disease or significant risk factors like uncontrolled hypertension or diabetes; if use is deemed necessary, it requires careful consideration.

What should I know about interactions with other medicines?

The interaction profile of Olfen-75 Sr (Diclofenac Sodium) is defined by mandatory restrictions and pharmacokinetic changes as documented by regulatory authorities. Co-administration is not recommended with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors and Ketorolac, due to an additive risk of serious gastrointestinal adverse events. Use is formally contraindicated for treating perioperative pain associated with coronary artery bypass graft (CABG) surgery.

Several agents are associated with increased risk or reduced efficacy. Combining Olfen-75 Sr with drugs that interfere with hemostasis, such as Warfarin, antiplatelet agents, and certain antidepressants (SSRIs/SNRIs), may increase the risk of serious gastrointestinal bleeding. Diclofenac may diminish the antihypertensive effect of ACE Inhibitors and Angiotensin Receptor Blockers (ARBs), as well as reduce the natriuretic effect of diuretics. In patients classified as elderly or having impaired renal function, the combination with ACE/ARBs poses a higher risk of renal function deterioration.

Pharmacokinetic interactions lead to increased plasma concentrations and potential toxicity of co-administered Lithium and Digoxin. Inhibitors of the CYP2C9 enzyme, such as Voriconazole, cause a documented increase in the systemic exposure of Diclofenac. Furthermore, Methotrexate exposure is increased due to reduced clearance. Finally, the consumption of alcohol may also increase the potential for serious gastrointestinal problems.

Mechanism of Action

Enzyme Inhibition and the Inflammatory Cascade

The core mechanism involves the non-selective inhibition of Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform, which blocks the conversion of arachidonic acid into prostaglandins (PGs), which are mediators within the inflammatory response. This action directly suppresses the synthesis of chemical components necessary to engage the inflammatory cascade, which results in the modulation of vascular permeability and vasodilation.

Modulation of Nociceptor Responsiveness

By reducing the level of prostaglandins, the drug modulates mechanisms that govern nociceptor responsiveness in the periphery. Prostaglandins are key chemicals that chemically amplify signals from peripheral nerves. Limiting their synthesis results in a shift toward a less sensitized state within the nociceptive pathway, which reduces the chemical amplification of neural signals from peripheral nerves.

Action on Central Thermoregulation

Diclofenac also modifies early molecular steps that shape central physiological outcomes by inhibiting COX activity within the hypothalamus, the brain's temperature control center. This mechanism suppresses the production of central pyretic mediators, resulting in the resetting of the hypothalamic thermoregulatory set-point.

Dosage and Administration Information

Olfen-75 Sr is a pharmaceutical preparation intended exclusively for oral administration. As a prolonged-release (SR) tablet, the physical integrity of the dose is essential: the tablet must be swallowed whole and must not be crushed, divided, or chewed. This constraint is a core requirement for ensuring the slow and consistent release of Diclofenac Sodium as intended by the sustained-release mechanism.

The overarching principle for the use of this medication is the administration of the lowest effective dose for the shortest duration necessary to provide symptom control. This principle dictates that the patient’s clinical requirement for the drug must be re-evaluated periodically throughout the course of therapy.

The typical adult dosing regimen starts at 75 mg to 100 mg per day, which may be administered once or twice daily, provided that the total daily intake does not exceed 150 mg. For proper administration, the tablet is directed to be taken with or immediately after food using a full glass of liquid. If a scheduled dose is missed, it should be skipped entirely, and the patient should resume the original schedule, avoiding the intake of a double dose.

Specific usage rules apply to certain populations. The medicine is not suitable for pediatric patients under 18 years of age due to a lack of established dosage and indications. For older adults (the elderly), the regimen must initiate at the lowest effective dosage, especially in individuals who are frail.

Recent Clinical Evidence

Research evidence / Overview of studies for Olfen-75 Sr

Evidence for Use in Chronic Joint Pain: Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

The prolonged-release (SR) formulation was evaluated in research contexts involving fluctuating symptoms common to Osteoarthritis (OA) and Rheumatoid Arthritis (RA). These investigations, often Randomized Controlled Trials (RCTs), primarily involved adult patients, including cohorts of older adults. Researchers monitored patient-reported outcomes related to physical discomfort and daily functioning using standardized scales. Findings reported how symptoms evolved in the observed populations during the short- to intermediate-term study periods.

However, the existing evidence is primarily structured to explore short-term symptom changes. Scientific reviews show that the research has not fully characterized the long-term effects, particularly concerning whether the medication appears to modify the progression of the underlying disease itself. Results apply only to the populations studied in the research setting.

Clinical Research for Ankylosing Spondylitis (AS)

The active ingredient, Diclofenac, in the SR formulation, research examined Ankylosing Spondylitis (AS) in specific clinical studies, including comparative trials. Studies primarily included adult patients with active signs of the condition, tracking outcomes such as Global Pain Intensity and disease activity indices. Certainty remains low when drawing conclusions from short-term data, and follow-up durations were limited for the primary comparative trials.

Understanding Study Design and Outcome Measures

The clinical trials research examined how symptoms change over time by focusing on outcomes linked to inflammatory or irritative states. The primary research examined changes in outcomes related to physical discomfort and physiological strain, using recognized scales. This contributes to the broader evidence landscape regarding how subjective patient experience is compared with objective clinical assessments.

Long-Term Evidence and Durability of Follow-up

The evidence base includes short-term RCTs and observational settings evaluating daily-life functioning. Primary controlled efficacy trials typically explored patient responses over periods ranging from six weeks to six months. While post-marketing studies have tracked patient patterns for longer periods (up to one to three years), long-term effects are not fully established and there is limited information for long-term outcomes beyond the measured follow-up duration.

Research Evidence in Defined Patient Subgroups

Research examined specific patient subgroups, particularly focusing on older adults with symptomatic arthritis. Findings for these cohorts describe group patterns, but the results apply only to the populations studied. Data for certain groups, such as those with highly complex comorbidities, remain insufficient.

Evidence Gaps and Areas for Future Research

Scientific reviews state that the existing research is limited or requires further investigation. Due to the study focus on symptomatic relief, the evidence highlights a gap regarding whether this medication appears to modify the underlying progression of disease. Furthermore, the overall evidence quality varies across studies, leading to some uncertainty in extrapolating findings broadly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Olfen-75 Sr (FAQ)

Q: What is the difference between Olfen-75 Sr and regular Olfen?

Olfen-75 Sr is a prolonged-release (SR) formulation of the active ingredient, diclofenac sodium. This means the drug is designed to release slowly and consistently over an extended period. Regular (immediate-release) forms of Olfen deliver the medicine more quickly into the body, which is the main difference in their intended action.

Q: How quickly should I expect Olfen-75 Sr to start working?

Because this is a sustained-release (SR) formulation, the drug is designed for prolonged action and consistent release. This prolonged-release feature may result in a slower onset of initial effect compared to immediate-release forms.

Q: How long does the effect of Olfen-75 Sr generally last?

The sustained-release (SR) formulation is specifically designed for a prolonged effect. Official product information states the design optimizes the maintenance of therapeutic drug levels through slow, consistent release to support sustained relief from discomfort and inflammation.

Q: What kind of pain is Olfen-75 Sr typically used for?

According to official regulatory documents, this medicine is indicated for the relief of the signs and symptoms of inflammatory conditions. This typically includes chronic conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, which are associated with long-term pain, stiffness, and inflammation.

Q: Why do doctors often prescribe Olfen-75 Sr for rheumatoid arthritis?

The drug is officially indicated for the relief of symptoms associated with inflammatory conditions, including Rheumatoid Arthritis. Its primary action is to reduce inflammation and pain, and the sustained-release formula is designed to assist in managing chronic symptoms over time.

Q: Can Olfen-75 Sr be taken with food or does it need to be on an empty stomach?

Official guidance states that the tablets should be taken with or immediately after food using a full glass of liquid. This method is often suggested to help mitigate the potential for stomach upset or irritation.

Q: Is it okay to stop taking Olfen-75 Sr suddenly?

Treatment with this medication is generally intended to relieve symptoms over a fixed period. Official information does not specify mandatory tapering, but as treatment is generally assessed periodically, discontinuing its use should be discussed with a healthcare provider.

Q: Can Olfen-75 Sr be used for dental pain?

The drug is indicated for general pain and inflammation. While the oral SR tablet is not consistently listed for acute dental pain as a primary indication across all regulatory documents, the active ingredient is generally used to treat pain and inflammation.

Q: What happens if I accidentally take two tablets instead of one?

Regulatory guidance suggests seeking immediate medical attention if an overdose is suspected. Overdose may present with symptoms such as stomach ache, feeling or being sick, and diarrhea.

Q: Is it normal to feel stomach discomfort after taking Olfen-75 Sr?

Official product information lists gastrointestinal disturbances such as nausea, vomiting, indigestion, and abdominal pain as common side effects. The tablet is directed to be taken with food, a common measure used to help mitigate this discomfort.

Q: Does Olfen-75 Sr cause dizziness or drowsiness?

Dizziness and headache are listed in regulatory documents as common side effects. Although less common, effects such as drowsiness have also been reported.

Q: Why do some people experience fluid retention or swelling with Olfen-75 Sr?

Official warnings note that fluid retention and edema (swelling) have been reported in association with Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy, including this medication. This risk is noted in official warnings, especially for individuals with existing cardiac or renal impairment.

Q: Does taking Olfen-75 Sr long-term have any common concerns?

Regulatory documents advise using the lowest effective dose for the shortest duration necessary to control symptoms. The risk of serious health issues, including cardiovascular thrombotic events (like heart attack or stroke) and severe gastrointestinal problems (such as bleeding or ulcers), has been associated with higher doses and longer duration of use.

Q: What are some less common but serious warning signs to look out for with Olfen-75 Sr?

Signs that have been reported include symptoms suggesting a heart attack or stroke (such as chest pain or difficulty breathing), signs of gastrointestinal bleeding (such as black or tarry stools or vomiting blood), and severe allergic reactions (such as a severe rash or swelling). These symptoms warrant prompt medical consultation.

Q: Is there a link between Olfen-75 Sr and changes in mood?

While less common, regulatory documents indicate that rare adverse events reported in post-marketing experience include effects such as confusion, depression, and anxiety.

Q: Can I take paracetamol (acetaminophen) while using Olfen-75 Sr?

Regulatory guidance strictly advises against combining this drug with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). However, paracetamol (acetaminophen) is not an NSAID and is not listed in official contraindications for co-administration. Any new medication or pain relief combination should always be reviewed by a healthcare provider.

Q: Are there known interactions between Olfen-75 Sr and alcohol?

Official product information indicates that the consumption of alcohol is known to potentially increase the risk of serious gastrointestinal problems while this medicine is being used.

Q: Can I take aspirin for a different condition while on Olfen-75 Sr?

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin, is generally not recommended due to an added risk of serious gastrointestinal adverse events. Use with low-dose aspirin for antiplatelet purposes has specific considerations that should be assessed by a healthcare provider.

Q: Does Olfen-75 Sr affect blood thinning?

This medication may affect the body's natural ability to clot blood, a process called hemostasis. Combining it with other blood thinners (anticoagulants) or antiplatelet agents increases the risk of serious bleeding events, particularly in the gastrointestinal tract.

Q: Can Olfen-75 Sr interact with herbal supplements?

Regulatory guidance suggests that there is not enough official information available to definitively state that complementary medicines, herbal remedies, and supplements are safe to take at the same time as this medication.

How should Olfen-75 Sr be stored and disposed of?

The storage and disposal of Olfen-75 Sr (diclofenac sodium prolonged-release tablets) must follow official regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C or 30 C (limit defined by local authority).
Protection	Must be protected from moisture.
Container	Keep the tablets in their original container or blister packaging to preserve product integrity.
Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Olfen-75 Sr tablets should not be disposed of in household rubbish or wastewater (e.g., sink or toilet). The official instruction is to return the medicine to a pharmacy or designated pharmaceutical waste collection point for proper disposal, following all local requirements.

Olfen-75 Sr